Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment

Previous data suggested that serum levels of soluble mesothelin (SM) are related to tumor size and may have prognostic significance in malignant pleural mesothelioma (MPM). We tested the hypothesis that this marker could also be useful for monitoring response to treatment. Serial measurements of SM...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of respiratory and critical care medicine Vol. 179; no. 10; pp. 950 - 954
Main Authors:	Grigoriu, Bogdan D, Chahine, Bachar, Vachani, Anil, Gey, Thomas, Conti, Massimo, Sterman, Daniel H, Marchandise, Genevieve, Porte, Henri, Albelda, Steven M, Scherpereel, Arnaud
Format:	Journal Article
Language:	English
Published:	New York, NY Am Thoracic Soc 15-05-2009 American Thoracic Society
Subjects:	Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Biomarkers, Tumor - blood Clinical death. Palliative care. Organ gift and preservation Enzyme-Linked Immunosorbent Assay Epithelial Cells - pathology Female Genetic Therapy - methods Humans Intensive care medicine Interferon-beta - biosynthesis Interferon-beta - genetics Male Medical sciences Mesothelioma - blood Mesothelioma - genetics Mesothelioma - therapy Middle Aged Pleural Neoplasms - blood Pleural Neoplasms - genetics Pleural Neoplasms - therapy Prognosis Treatment Outcome Human Intensive care Prognosis Respiratory disease Malignant tumor Treatment marker Pleural disease neoplasm Malignant pleural mesothelioma Pleura Resuscitation Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Previous data suggested that serum levels of soluble mesothelin (SM) are related to tumor size and may have prognostic significance in malignant pleural mesothelioma (MPM). We tested the hypothesis that this marker could also be useful for monitoring response to treatment. Serial measurements of SM were determined in 40 patients diagnosed with MPM and subjected to gene-transfer therapy using intrapleural infusion of an adenoviral vector expressing human IFN-beta or conventional treatment (mainly chemotherapy). In patients with baseline SM levels greater than 1 nM/L and disease progression after therapy, SM levels increased by 2.1 nM/L at two, 5.2 nM/L at four and 1.3 nM/L at 6 months. Patients with initial SM below 1 nM/L had a similar but more moderate increase of SM over time. Patients who responded to treatment or were considered stable had an initial small decrease of SM followed by a return to baseline values after 6 months of follow-up. In patients with baseline SM levels greater than 1 nM/L, increasing levels were associated with a significantly shorter median survival than in patients with stable or decreasing SM levels (4.4 vs. 27.7 months; P = 0.012). Increasing serum levels of SM were associated with disease progression and worse outcome, whereas stable or decreasing values suggested response to treatment. If confirmed in larger series, SM could be used to monitor patients with malignant pleural mesothelioma under treatment.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1073-449X 1535-4970
DOI:	10.1164/rccm.200807-1125OC